Hong Kong Stock Movement | HENLIUS (02696) Rises Nearly 5% in Early Session as HLX22 Head-to-Head Trial with Keytruda for Gastric Cancer Holds Successful US Investigator Meeting

Stock News02-03 11:25

HENLIUS (02696) saw its shares climb nearly 5% during the morning trading session. At the time of writing, the stock was up 4.1%, trading at HK$58.4, with a turnover of HK$19.1632 million.

On the news front, HENLIUS recently held a successful offline investigator meeting for the HLX22-GC-301 study in San Francisco, USA.

The meeting focused on the company's international multi-center Phase III clinical trial, HLX22-GC-301, which is evaluating the investigational novel epitope anti-HER2 monoclonal antibody HLX22 in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive advanced gastric cancer.

Notably, HENLIUS also announced recently that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical trial for the combination of injectable HLX43, HLX07, and serplulimab injection for the treatment of advanced solid tumors.

HENLIUS plans to commence a Phase II clinical study of this combination therapy in China once the necessary conditions are met.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment